Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- The Healthcare MBA: One Fast Track in a Slow Economy
- The bottom line: Healthcare is hiring and B-schools can't churn out enough MBAs to fill jobs in the $2.26 trillion industry. Top...
- Articles 2009-02-09
Additional Resources
- The Pfizer-Amgen Deal Worst-Case Scenario
- Deutsche Bank analyst Barbara Ryan has again gone public with her desire to see Pfizer get off its pile of cash and make a dramatic mega-buy that would solve its pipeline hole. This time she thinks Amgen ought to be the target. BNET readers have been down this road before....
- Blog posts 2008-12-17
- Amgen More Dependent on Denosumab Than Ever, But What If FDA Delays Approval?
- Amgen's Q4 results showed, again, how dependent the company is on the FDA coming up with a solid approval for denosumab, its osteoporosis drug. Revenues were down a little bit to $3.6 billion, but expenses ballooned. The revenue yield on its sales dollars collapsed 23 percent from...
- Blog posts 2009-01-27
- An Osteoporosis Blockbuster for Amgen?
- By Arlene Weintraub Wall Street has set an exceptionally high bar for Amgen AMGN's new bone-loss treatment. Shares of the world's largest biotechnology company have jumped 27% in the past three months, to 60, largely on news of clinical trials that showed the drug is as at least as effective,...
- News items 2009-08-11
- AMGEN.(to open drug research centre in Cambridge, MA)(Brief Article)
- AMGEN has broken ground for Amgen Center Cambridge, a new facility dedicated to drug research and drug discovery, marking Amgen's ... AMGEN has broken ground for Amgen Center Cambridge, a new facility dedicated to drug research and drug discovery, marking Amgen's entry into the...
- Research articles 1999-11-15
- Amgen Announces the Formation of Amgen Ventures; Venture Capital Fund Designed to Provide Resources to Help Advance Early-Stage Biotechnology Companies and Human Therapeutics
- THOUSAND OAKS, Calif. -- Amgen Inc. (NASDAQ:AMGN), the world's largest biotechnology company, today announced the formation of Amgen Ventures, a corporate venture capital fund designed to provide emerging biotechnology companies with resources to develop pioneering discoveries focused on human therapeutics. Amgen Ventures reflects Amgen's commitment to helping patients through cutting-edge...
- Research articles 2004-11-11
- Amgen Names Yuji Orihara President, Amgen KK
- THOUSAND OAKS, Calif. -- Amgen (NASDAQ:AMGN), today announced the appointment of Yuji Orihara to the position of president and representative director, Amgen KK, effective immediately. Amgen KK was formed in 1992 in Japan as a wholly owned subsidiary of Amgen Inc. Orihara will be responsible for all aspects of Amgen's...
- Research articles 2006-12-01
- Full Transcript of Amgen’s 3Q05 Conference Call — Prepared Remarks (AMGN)
- Earnings Call ExcerptHere’s the entire text of the prepared remarks from Amgen’s (ticker: AMGN) Q3 2005 conference call. The Q&A is in a separate article. We recognize that this transcript may contain inaccuracies - if you find any, please post a comment below and we’ll incorporate your corrections. And...
- Earnings calls 2005-10-26
- Amgen Posts Medical Education and Foundation Grants and Donations as Part of the Company's 'Clearly Amgen' Initiative
- THOUSAND OAKS, Calif. -- Amgen (NASDAQ: AMGN) today posted to the company's Web site grants and donations made by the Amgen Medical Education department AmgenMED and the Amgen Foundation. The posting is the latest element of Clearly Amgen, a section of the Company's Web site designed to provide clear and...
- Research articles 2008-05-22
- Amgen CEO Sharer: Options? No Thanks. I'll Just Take the Cash.
- The total value of compensation paid to the top five executives at Amgen rose slightly in 2008, to $35.9 million from $34 million in 2007. The team largely met its revenue and EPS goals. This seemingly modest state of affairs came to pass because the team was...
- Blog posts 2009-03-11
- Amgen Sued By 15 States Over Aranesp Kickbacks
- The lawsuit charges Amgen - along with a specialty group purchasing organization known as International Nephrology Network and the ASD Healthcare wholesaler - with offering kickbacks to medical providers to increase sales of its Aranesp anemia drug, Aranesp. The multi-state suit, by the way, joins a whistleblower lawsuit filed in...
- News items 2009-10-30
- FDA Delivers Another Blow to Amgen?s Anemic Drug Sales
- The Simplified Investor submits: Amgen (NYSE:AMGN) made its reputation as one of the premier firms in the biotechnology industry with its blockbuster anemia drugs, Aranesp and Epogen. Worldwide sales of anemia drugs made up around half of Amgen’s $14.8B revenue in 2007 and an even larger percentage of its...
- External links 2008-08-01
- Amgen Inc. (Active Pharmaceutical Ingredient Watch).(stock repurchase)(Brief Article)
- AMGEN Inc. has authorized an additional repurchase of up to $2 billion in Amgen common stock through June 30, 2004. The company has roughly $260 ... AMGEN Inc. has authorized an additional repurchase of up to $2 billion in Amgen common stock through June...
- Research articles 2002-06-17
- AMGEN Inc.(Brief Article)
- AMGEN Inc. has entered into a development and clinical supply agreement with Bioject Medical Technologies Inc. for the delivery of an Amgen product with ... AMGEN Inc. has entered into a development and clinical supply agreement with Bioject Medical Technologies Inc. for the delivery...
- Research articles 2000-03-06
- Why Amgen Doesn't Want a Big Sales Force for Denosumab
- Amgen wants to market its new twice-yearly osteoporosis injection, denosumab, without a massive sales force. Instead, the company said it wants to rely more heavily on the internet. The move will produce an interesting experiment that tests whether companies really need heavy sales forces to sell blockbuster...
- Blog posts 2008-11-10
- FDA to Consider Lower Standards for Amgen and ImClone in Cancer Studies
- In its review of applications for ImClone's Erbitux and Amgen's Vectibix, the FDA has released a statement simultaneously frowning upon retrospective analyses of drug studies and suggesting a path for their use in new indication approvals. The statement says in part: There are multiple examples of “retrospective†or post-hoc...
- Blog posts 2008-12-12
- Fitch Rates Amgen's New Senior Unsecured Notes 'A'
- CHICAGO -- Fitch Ratings has assigned an 'A' rating to Amgen Inc.'s Amgen public issuance of senior unsecured debt, comprising 10-year and 30-year senior unsecured notes. The Rating Outlook is Stable. Proceeds from the new senior unsecured debt are expected to be used to redeem all or some of Amgen's...
- Research articles 2008-05-20
- Amgen Fired Manager Over Adverse Events?
- Amgen fired a project manager for complaining that the pharmaceutical giant underreported "adverse events" involving "every product it markets," the man claims in a lawsuit filed in Superior Court in Ventura, Ca., Courthouse News reports. Shawn O'Brien says Amgen continues to underreport "post marketing adverse event" data to the FDA...
- News items 2009-10-20
- Amgen and Catalytica Report Favorable 4th Quarter Earnings.
- THOUSAND OAKS, CALIF.-BASED Amgen Inc. posted a 34 percent increase in earnings per share EPS during the fourth quarter of 1998. Amgen earned 90 cents per share, up from 67 cents in the fourth quarter of 1997. The company's net income for the qua ...
- Research articles 1999-02-08
- Amgen and Praecis Form $100 Million Alliance.
- AMGEN HAS ENTERED into a collaboration to codevelop and market abarelix, a gonadotropin releasing hormone GnRh antagonist developed by Praecis Pharmaceuticals Inc. As part of deal, Amgen will invest about $100 million in 1999. The company s AMGEN...
- Research articles 1999-03-15
- << Previous
- page 1 of 1
- Next >>
Presented by American Express